{"preliminary_commentary":{"by_channel":{"x_thread":5,"podcast":3,"youtube":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06743126\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"SUPRAME","nct_id":"NCT06743126","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=suprame-nct06743126. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"SUPRAME","arms":[{"description":"Non-myeloablative chemotherapy for lymphodepletion (LD) over 4 days using fludarabine (FLU) and cyclophosphamide (CY), one-time administration of IMA203, and adjunctive therapy with low dose interleukin (IL)-2 for up to 10 days, starting approximately 24 h after IMA203 infusion, optional bridging therapy","label":"Experimental arm","type":"EXPERIMENTAL"},{"description":"Investigator's choice of treatment approved by the respective Competent Authority (nivolumab plus relatlimab \\[Opdualag®\\], lifileucel, nivolumab, pembrolizumab, ipilimumab, or chemotherapy \\[e.g., dacarbazine, temozolomide, paclitaxel, alb-bound paclitaxel, or paclitaxel plus carboplatin\\]) as determined by the site investigator in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC), optional bridging therapy.","label":"Control arm- investigator's choice","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2031-10","type":"ESTIMATED"},"conditions":["Melanoma, Cutaneous Malignant"],"enrollment":{"count":360,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"IMA203","otherNames":["anzutresgene autoleucel","anzu-cel"],"type":"BIOLOGICAL"},{"name":"nivolumab plus relatlimab","otherNames":["Opdualag®"],"type":"BIOLOGICAL"},{"name":"lifileucel","otherNames":["AMTAGVI"],"type":"BIOLOGICAL"},{"name":"nivolumab","otherNames":["Opdivo®"],"type":"BIOLOGICAL"},{"name":"pembrolizumab","otherNames":["Keytruda®"],"type":"BIOLOGICAL"},{"name":"ipilimumab","otherNames":["Yervoy"],"type":"BIOLOGICAL"},{"name":"Dacarbazine","otherNames":["DTIC-Dome"],"type":"DRUG"},{"name":"temozolomide","otherNames":["Temodar"],"type":"DRUG"},{"name":"paclitaxel","otherNames":["Taxol"],"type":"DRUG"},{"name":"paclitaxel plus carboplatin","otherNames":["Carbo/Taxol®"],"type":"DRUG"},{"name":"Albumin-Bound Paclitaxel","otherNames":["Abraxane®"],"type":"DRUG"}],"last_update":"2026-08-18","lead_sponsor":"Immatics US, Inc.","official_title":"A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator's Choice of Treatment in Patients With Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free survival assessed by BICR","timeFrame":"up to 5 years post first treatment of last patient"}],"references":[],"start_date":{"date":"2025-01-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","url":"https://clinicaltrials.gov/study/NCT06743126"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/suprame-nct06743126"}